“ALTUVIIIO has protected me, and I have not had a [breakthrough] bleed since switching.”*
A less frequent dosing regimen
Before starting on ALTUVIIIO, I rarely infused, even though I was supposed to 3 times a week. I really wanted fewer infusions and longer protection. That would make it easier to stick to my regimen. And I felt excited but also anxious about the prospect of switching.
Considering the switch
When discussing making the switch with my doctor and care team, I didn’t feel swayed or pressured. They gave me all the facts and answered all my questions, and then some. If anyone was withholding anything, it was me. I never downplayed my condition or the severity of bleeds, but I wasn’t always honest about how often I infused.
A smooth transition
Once we made the decision to change, the transition to ALTUVIIIO was easy for me. My care team provided training and assistance when I switched to home care for my infusions. Since starting ALTUVIIIO, my doctor and I have been happy with the results.
Living with confidence
I have not had a bleed since switching to ALTUVIIIO.* It’s been more than 700 days since my last bleed. ALTUVIIIO has provided bleed protection and a dosing regimen I have been able to stick to. And while I was willing to do everything before, I certainly feel confident enough to continue doing everything I want to do now.
A good doctor-patient relationship
Throughout the process, I’ve appreciated how knowledgeable my care team is about available medications and how they explain everything. It allowed me to make an informed decision and to be comfortable with it. I’d also encourage all doctors to get patients’ honest testimony and to ask if they have any concerns with their current treatment. That way, doctors can let their patients know if a different medication may be a good fit for them.
This testimonial reflects one patient’s experience and has not been clinically evaluated. It is not intended to imply typical outcomes or substitute for clinical evidence. Mickey is a promotional speaker compensated by Sanofi.
*Based on patient data collected December 2025.
